Friday, 18 Aug 2017

You are here

The RheumNow Week in Review – 21 April 2017

Dr. Jack Cush reviews highlights from the past week on RheumNow.com:

  1. Long term followup of RA pts on Norfolk registry demonstrate better SURVIVAL when DMARDs are started early (<6 mos) https://t.co/Wy2OVFuw7l
  2. How Pfizer makes most of its $52.8 billion in 2016 - Surprisingly most from Prevnar 13 at $5.7 bill/year! https://t.co/bSy2GjLlj9
  3. Neutrophil to Lymphocyte ratio useful in assessing SLE w/ lympho/leukopenia from Rx or SLE? High (>2) w/ Dz activity https://t.co/NrbQaQ2xtA
  4. Acute Arthritis study shows ultrasound gout findings show sensitivity/specificity for 1) double contour 42/92%, 2) Intraarticular aggregates 58/92%, and 3) tophi 40/100.; all with a PPV 88-100% https://t.co/pf2T3JBAeU
  5. In animal models, high fat, high carbohydrate diet (junk food) promotes cartilage damage and osteoarthritis. https://t.co/70KgIrzh74
  6. Corrona study 1,567 PsA shows patients w/ dactylitis or enthesitis had more Dz activity, Pain, Fatigue, low work,HAQ https://t.co/2UcTOZKhYf
  7. Osteoarthritis Initiative 4367 pts shows 15% w/ recurrent falls, increased by 22-25% w/ opioid or antidepressant use https://t.co/LiIEANObvj
  8. Lyme disease hits 2016 record high in Maine; 1464 cases, up by 21% from 2015. Most increased Penobscot Co since 201… https://t.co/3LPj5wdisM
  9. Data from OP/OA mtg in Italy says Knee Osteoarthritis is associated wth a 13% higher risk of developing hypertension (P=.03) https://t.co/pEKJH0R7wj
  10. Norway population study shows self-reported dx of RA & AS highly inaccurate, 19% RA, 16% AS verified by hosp records https://t.co/zc2zIb1ZZY
  11. FDA Delays Baricitinib Decision
  12. The Cost of Not Taking Medicine
  13. Anti-IL-23 Therapy Effective in Crohn's Disease
  14. Paradoxical Toxicities with TNF Inhibitors
Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Rheumatologists' Comments

I am working in locum in Wisconsin and note that the EHR frequently lists a "problem" (not diagnosis) of Lyme disease. The majority of such patients have poorly documented disease manifestations with non-confirmatory serologies upon repeat or Western Blot. The majority are "diagnosed" and empirically treated in the ER or urgent care setting by a primary care doc based on non-specific complaints (when I started practice in 1978 such patients were labeled "chronic brucellosis", now they are labeled "chronic Lyme disease). Hence I am slow to accept any "reports" regarding the incidence of Lyme disease. More likely its the incidence of mis-dagnosis of Lyme disease. A + PPD does not equate to active TB (only exposure), and +serolgy for Lyme does not equate to active disease, only expoure to B. Bergdorfi.

More Like This

The RheumNow Week in Review – 18 August 2017

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report includes new data on lupus survival, pediatric lupus guidelines from SHARE, room temperature storage of etanercept, over or under-testing by rheumatologists and failure of pain meds to treat pain.

The RheumNow Week in Review – 11 August 2017

The RheumNow Week in Review caps the week's news every Friday. Dr Jack Cush reviews the news, journal reports and important events from the past week in rheumatology.  This week's news highlights include new data on the incidence of arthritis, lag times in patient referral, criteria for referral and why/how weather change affects arthritis pain.

Criteria for Early Referrals from Primary Care

Early diagnosis and early intervention has been the mantra of all who manage musculoskeletal (MSK) diseases for decades. While the rules for referral may be clear to some, the lack of uniformity and promotion amongst primary care providers is less certain.

MSK Ultrasound Now Standard for Rheumatology Training

In the United States, musculoskeletal ultrasound (MSUS) in rheumatology has grown significantly in the last few decades. Ten years ago, more than half of rheumatology fellows had training or exposure to MSUS. A current survey of training programs shows that 94% provide MSUS training.

The RheumNow Week in Review – 4 August 2017

Dr. Jack Cush reviews new FDA decisions on sirukumab and tofacitinib as well as other news items from the past week on RheumNow.com.